RxDoctor Payments DataLook up a doctor →

Robert Wilkins, MD

Interventional Cardiology · Hattiesburg, MSNPI 1598875304

Payments from drug & device makers

$106,436in general payments, 2019–2025

Across 294 payments — averaging $362.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$56K
  • Surmodics, Inc.$43K
  • Abbott$2K
  • Medtronic$1K
  • Abiomed$879
  • Inari Medical, Inc.$652
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,51198%
  • Gifts$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,436 in reported general payments places this provider in the 85th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,398,932
Medicare patients
1,940
Services billed
13,835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban563$485,840
EntrestoSacubitril/Valsartan174$143,701
XareltoRivaroxaban114$87,541
BrilintaTicagrelor145$80,223
JardianceEmpagliflozin20$22,391
Ranolazine ErRanolazine151$7,990
ClopidogrelClopidogrel Bisulfate721$4,722
Amiodarone Hcl311$3,965
Metoprolol Succinate357$3,677
Atorvastatin Calcium245$1,380
Isosorbide Mononitrate ErIsosorbide Mononitrate172$1,260
Propafenone Hcl28$1,121
Metoprolol Tartrate346$1,038
Nitroglycerin81$1,038
Carvedilol194$931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$485,840563 claims
NovartisEntresto$277$143,701174 claims
Boehringer IngelheimJardiance$43$22,39120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →